EssilorLuxottica's Valuation Pillar Cracks as Kepler Cheuvreux Slashes Rating and Target
Published on 09/19/2026 at 21:10 | Editorial boerse-global.de
EssilorLuxottica found itself on the defensive this week after Kepler Cheuvreux executed a sharp about-face on the Franco-Italian eyewear giant, cutting its recommendation straight from "Buy" to "Reduce" and hacking the price target down to 135 euros from 244 euros. The downgrade, reported by Bloomberg, lands squarely on the company's most sensitive nerve: the smart-glasses narrative that has long underpinned its premium multiple.
The market wasted little time registering the verdict. The stock shed 1.9 percent to close at 138.70 euros, having touched a fresh 52-week low of 138.00 euros during Friday's session. Kepler's analysts pointed to three converging pressures — fading momentum in data glasses, tighter regulatory scrutiny over data privacy, and persistent governance uncertainty surrounding the Del Vecchio family holding.
A Growth Engine Under Scrutiny
Smart eyewear had been positioned as a central lever for future expansion, justifying the valuation premiums the group commanded in recent years. With market expectations for that technology cooling and regulatory hurdles mounting, one of the load-bearing pillars of the bull case is now wobbling.
The downgrade also forces investors to confront an uncomfortable question: can the group's operating earnings power withstand the mounting strain, or does the shifting landscape justify a permanently lower valuation? At 135 euros, Kepler's target implies fair value more than 40 percent below prior levels — a direct challenge to the margin and growth assumptions that management has defended.
Board Backs Leadership, but the Slide Continues
Governance concerns have compounded the technological doubts. Roughly three weeks ago, Leonardo Maria Del Vecchio, son of the company's founder, resigned as Ray-Ban chief and Chief Strategy Officer following disagreements over strategic direction. The stock has lost 13.8 percent since that departure, which fueled capital-market doubts about internal cohesion.
Should investors sell immediately? Or is it worth buying EssilorLuxottica?
The supervisory board moved to counter those fears, unanimously reaffirming full confidence in Chairman and CEO Francesco Milleri, Deputy CEO Paul du Saillant, the leadership team, and the corporate strategy about a week ago. The board explicitly anchored its support in the company's solid operating results. Yet the gesture did little to steady the shares — they have slipped 6.3 percent since that vote of confidence.
Buyback and Clinical Data as Counterweights
Management has not stood idle. In late August, EssilorLuxottica launched a share buyback program, mandating a securities services provider to acquire up to 5,000,000 of its own shares. The company framed the move as a signal of confidence in long-term value creation and its prospects. Purchases under the program are already underway and, at current levels, could serve as a technical buffer against further selling pressure.
There is also fresh scientific backing for the product pipeline. In August, the peer-reviewed journal JAMA Ophthalmology published 24-month results from a US clinical study of Essilor's Stellest lenses, reinforcing the group's positioning in the high-margin myopia correction segment. Should EssilorLuxottica convert such technological advances into accelerated organic growth, the recent selloff could ultimately look like an overshoot — opening room for a recovery toward earlier valuation ranges.
What Could Go Wrong
The bear case tracks the concerns embedded in Kepler's 135-euro target. If other research houses follow suit, a sustained withdrawal of institutional money becomes a real threat. The stock's decline already reflects an erosion of trust that strategic turbulence could deepen further.
Add to that the risk that headwinds in the consumer goods sector dampen demand for frames and lenses more sharply than anticipated. And if the buyback of up to five million shares proves unable to brake the slide, a key instrument of price support loses its potency. In that scenario, the market could settle on permanently lower multiples for both revenue and earnings.
The Level to Watch
For now, the 138.00-euro mark represents the line in the sand. As long as it holds, a volatile bottoming process remains possible — though investors should brace for a potential test of the 135-euro level that Kepler has staked out as fair value. A decisive break below that floor would risk ushering in a fresh technical downtrend.
The next real litmus test comes with the operating performance of the months ahead. Shareholders will be watching closely to see whether EssilorLuxottica can back up management's reiterated earnings trajectory with hard numbers at the next scheduled results. Until then, the stock remains in a delicate phase of price discovery, with new analyst verdicts and the steady execution of the buyback program setting the tempo. Year to date, the shares are down 49 percent.
Ad
EssilorLuxottica Stock: New Analysis - 19 September
Fresh EssilorLuxottica information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
